5th Floor, Brigade Towers,
Financial District, Gachibowli,
Hyderabad - 500032,
The In-Vitro diagnostics market is segmented by Test Type, Product (Instrument, Reagent, Others), Usability, Application, End-User and Geography
Fastest Growing Market:
Global In-Vitro Diagnostic market is expected to grow with a CAGR of 4.81% over the forecast period. The growth of the global IVD market can be attributed to the high prevalence of chronic and infectious diseases. Chronic diseases are a growing global challenge, and according to WHO estimates, account for approximately 60% of all deaths, worldwide. The current market is also growing due to the use of advanced technologies in the IVD market. There has been a paradigm shift from traditional diagnostics to a new generation diagnostics that work at the gene level. This was made possible by the inclusion of advanced technologies, such as genetic testing, molecular diagnostics, polymerase chain reaction (PCR) and next-generation sequencing (NGS).
As per the scope of this report, in vitro diagnostics involves medical devices and consumables that are utilized to perform in vitro tests on various biological samples. They are used for the diagnosis of various medical conditions, such as Diabetes and Cancer etc. The In-Vitro diagnostics market is segmented by test type, product, usability, application, end-user and geography.
|By Test Type|
|Disposable IVD Devices|
|Reusable IVD Devices|
|By End Users|
|Hospitals & Clinics|
|Other End Users|
Report scope can be customized per your requirements. Click here.
In the product segment of the In-Vitro Diagnostic market, the reagent is believed to have the largest market size and is expected to witness a CAGR of 4.8% in the forecast period.
The reagent segment of the market studied includes chemical, biological, or immunological components, solutions, or preparations intended by the manufacturer to be used during the in-vitro diagnosis process. Given the high cost of many diagnostic platforms, it is common for manufacturers to lease equipment instead of selling technology outright to end users. In these arrangements, the lease is tied to contracts to purchase associated reagents or assays for the equipment over the life of the contract. Many diagnostic companies have in excess of 75% of sales from consumables such as assays and reagents, and such agreements guarantee the generation of cyclic revenues associated with the sale of reagents and other consumables.
Many developing countries have established local immunoassay reagent programs to manufacture low-cost, high-quality immunoassay reagents. Kits from these projects are now beginning to become available and are likely to fuel the market expansion.
To understand key trends, Download Sample Report
North America currently dominates the market for In-Vitro Diagnostic and is expected to continue its stronghold for a few more years. This region is expected to increase its market share in the future owing to the well-established healthcare industry and rising prevalence of the chronic diseases in the region. The United States holds the majority of the market in the North America region; this is due to the rising healthcare expenditure, along with rapid adoption of point-of-care testing.
To understand geography trends, Download Sample Report.
The In-Vitro Diagnostic market is highly competitive and consists of several major players. In terms of market share, few of the major players currently dominate the market. However, with technological advancement and product innovation, mid-size to smaller companies are increasing their market presence by introducing new products at lesser prices. Companies like Thermo Fischer Scientific Inc., Abbott Laboratories, Siemens Healthcare GmbH and F. Hoffmann-La Roche AG. holds the substantial market share in the In-Vitro Diagnostic market.
1.1 Study Deliverables
1.2 Study Assumptions
1.3 Scope of the Study
2. RESEARCH METHODOLOGY
3. EXECUTIVE SUMMARY
4. MARKET DYNAMICS
4.1 Market Overview
4.2 Market Drivers
4.2.1 High Prevalence of Chronic Diseases
4.2.2 Increasing Use of Point-of-care (POC) Diagnostics
4.2.3 Advanced Technologies in In-vitro Diagnostic Products
4.2.4 Increasing Awareness and Acceptance of Personalized Medicine and Companion Diagnostics
4.3 Market Restraints
4.3.1 Stringent Regulations Regarding Product Approvals
4.3.2 Cumbersome Reimbursement Procedures
4.4 Porter's Five Force Analysis
4.4.1 Threat of New Entrants
4.4.2 Bargaining Power of Buyers/Consumers
4.4.3 Bargaining Power of Suppliers
4.4.4 Threat of Substitute Products
4.4.5 Intensity of Competitive Rivalry
5. MARKET SEGMENTATION
5.1 By Test Type
5.1.1 Clinical Chemistry
5.1.2 Molecular Diagnostics
5.1.3 Immuno Diagnostics
5.1.5 Other Types
5.2 By Product
5.2.3 Other Products
5.3 By Usability
5.3.1 Disposable IVD Devices
5.3.2 Reusable IVD Devices
5.4 By Application
5.4.1 Infectious Disease
5.4.5 Autoimmune Disease
5.4.7 Other Applications
5.5 By End Users
5.5.1 Diagnostic Laboratories
5.5.2 Hospitals & Clinics
5.5.3 Other End Users
5.6.1 North America
18.104.22.168 United States
22.214.171.124 United Kingdom
126.96.36.199 Rest of Europe
188.8.131.52 South Korea
184.108.40.206 Rest of Asia-Pacific
5.6.4 Middle-East and Africa
220.127.116.11 South Africa
18.104.22.168 Rest of Middle-East and Africa
5.6.5 South America
22.214.171.124 Rest of South America
6. COMPETITIVE LANDSCAPE
6.1 Company Profiles
6.1.1 BioMérieux SA
6.1.2 Danaher Corporation
6.1.3 F. Hoffmann-La Roche Ltd
6.1.4 Becton, Dickinson and Company
6.1.5 Bio-Rad Laboratories, Inc.
6.1.6 Abbott Laboratories
6.1.7 Arkray Inc.
6.1.8 Sysmex Corporation
6.1.9 Ortho Clinical Diagnostics
6.1.10 Siemens Healthcare GmbH
6.1.11 Thermo Fischer Scientific Inc
7. MARKET OPPORTUNITIES AND FUTURE TRENDS
**Competitive Landscape covers- Business Overview, Financials, Products and Strategies, and Recent Developments